Liu J, Wang F, Wang Y, He S S, Wang Y Y, Wei L H
Department of Clinical Laboratory Center, Gansu Provincial People's Hospital, Lanzhou, Gansu, China.
Gansu Provincial Clinical Research Center for Laboratory Medicine, Lanzhou, Gansu, China.
Hippokratia. 2023 Apr-Jun;27(2):37-40.
We aimed to evaluate in this study the diagnostic value of the plasmin-α2-plasmin inhibitor complex in patients with malignant tumors and venous thromboembolism (VTE).
A total of 58 patients with confirmed malignant tumors and VTE were selected, and their plasma samples were collected within 24 hours after VTE diagnosis. We also selected 60 patients with malignant tumors who were hospitalized at the same time and did not have VTE following imaging examination. Their plasma samples were collected within 24 hours after admission and were compared to those of the VTE group concerning the levels of plasmin-α2-plasmin inhibitor (PIC), thrombin-antithrombin complex (TAT), tissue-type plasminogen activator-inhibitor complex (tPAI-C), and thrombomodulin (TM). We used the receiver operator characteristic (ROC) curve to evaluate the diagnostic efficacy of each index regarding malignant tumors accompanied by VTE.
PIC, TAT, and tPAI-C were significantly higher in the group with malignant tumors and VTE compared to the group with malignant tumors without thrombosis (p =0.010, p =0.001, and p =0.003, respectively). In contrast, we found no significant difference in TM levels between the two groups (p =0.483). The area under the curve (AUC) of PIC, TAT, and tPAI-C regarding patients with malignant tumors and VTE was 0.852, 0.636, and 0.655, respectively, demonstrating diagnostic values for those cancer patients suffering VTE. PIC had the highest diagnostic efficiency in those patients with malignant tumors and VTE, while the AUC of TM was 0.537, so its diagnostic value for VTE-complicated malignant tumors was limited.
PIC has a sufficient value for the early diagnosis of VTE in patients with malignant tumors. HIPPOKRATIA 2023, 27 (2):37-40.
本研究旨在评估纤溶酶-α2-纤溶酶抑制物复合物在恶性肿瘤合并静脉血栓栓塞症（VTE）患者中的诊断价值。
共选取58例确诊为恶性肿瘤并患有VTE的患者，在VTE诊断后24小时内采集其血浆样本。我们还选取了60例同期住院且经影像学检查未发生VTE的恶性肿瘤患者，在入院后24小时内采集其血浆样本，并将其与VTE组患者的血浆样本在纤溶酶-α2-纤溶酶抑制物（PIC）、凝血酶-抗凝血酶复合物（TAT）、组织型纤溶酶原激活物-抑制物复合物（tPAI-C）和血栓调节蛋白（TM）水平方面进行比较。我们使用受试者工作特征（ROC）曲线来评估各指标对合并VTE的恶性肿瘤的诊断效能。
与无血栓形成的恶性肿瘤组相比，恶性肿瘤合并VTE组的PIC、TAT和tPAI-C水平显著更高（分别为p = 0.010、p = 0.001和p = 0.003）。相比之下，我们发现两组之间的TM水平无显著差异（p = 0.483）。PIC、TAT和tPAI-C对恶性肿瘤合并VTE患者的曲线下面积（AUC）分别为0.852、0.636和0.655，表明这些指标对患有VTE的癌症患者具有诊断价值。PIC在恶性肿瘤合并VTE患者中具有最高的诊断效率，而TM的AUC为0.537，因此其对合并VTE的恶性肿瘤的诊断价值有限。
PIC对恶性肿瘤患者VTE的早期诊断具有足够的价值。《希波克拉底》2023年，27（2）：37 - 40。
